Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 2Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Large-Cell, Anaplastic 4Granuloma, Plasma Cell 3Hematologic Neoplasms 2Rhabdomyosarcoma 1Neuroblastoma 1Neoplasms 1Lymphoma, B-Cell 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Temozolomide 4Specimen Handling 3Magnetic Resonance Spectroscopy 3Paclitaxel 2Gemcitabine 2Filgrastim 2Drug Therapy 2Cognitive Behavioral Therapy 2Blood Specimen Collection 2Azacitidine 2vocimagene amiretrorepvec 1trametinib 1sonidegib 1sargramostim 1ruxolitinib 1rucaparib 1ribociclib 1repotrectinib 1imetelstat 1fludarabine 1epacadostat 1dostarlimab 1depatuxizumab 1ceritinib 1cemiplimab 1cc-486 1carboxyamido-triazole 1acalabrutinib 1abiraterone 1Uncertainty 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioblastoma × ceritinib × Lymphoid × Clear all
NCT02465528 2019-12-27

Ceritinib Rare Indications Study in ALK+ Tumors

Novartis

Phase 2 Terminated
22 enrolled 16 charts
CNSLymphoidOther hematologic neoplasmPlasma cell

Glioblastoma, Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡